TNGX

Tango Therapeutics, Inc.

NasdaqGMUSDEQUITY DELAYED

24.02

▲ 0.51 (2.17%)

MARKET · —

Price

Open

23.83

Prev close

23.51

Day high

24.36

Day low

23.48

Volume

2.49M

Market cap

—

P/E (TTM)

—

52W range

6.25 – 34.39

Trailing performance

Price return · vs SPY

Returnvs SPY

-6.72% -5.4%

-13.01% -16.7%

+10.45% +7.4%

+95.74% +84.7%

YTD

+169.53% +157.2%

+253.78% +233.8%

+249.12% +175.0%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

25.42

-5.49% from price

SMA 20

26.48

-9.81% from price

SMA 50

28.42

-15.96% from price

SMA 100

25.77

-6.79% from price

SMA 200

18.81

+26.93% from price

EMA 12

25.52

-5.88% from price

EMA 26

26.53

-9.46% from price

EMA 50

26.68

-9.95% from price

RSI (14)

36.5

Neutral

MACD (12,26,9)

-1.01

Hist -0.32

ATR (14)

1.51

6.30% of price

Realised vol 30D

64.5%

Annualised

Bollinger upper

29.53

20, 2σ

Bollinger lower

23.43

20, 2σ

50 / 200 cross

Golden

28.42 vs 18.81

Trend bias

Above 200

+26.93%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.40

More volatile than market

Correlation to SPY

0.18

Largely independent

Realised vol 30D

64.5%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-29.2%

Peak to trough

Max drawdown 5Y

-93.6%

Peak to trough

ATR 14

1.51

6.30% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 24.02

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

TNGX · links out to the publisher

TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses Zacks · 10d ago Tango Therapeutics Q2 Net Loss Widens MT Newswires · 11d ago Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights GlobeNewswire · 11d ago Tango Therapeutics Executive Chair Barbara Weber Departs MT Newswires · 15d ago Tango Therapeutics Announces Executive Chair Transition GlobeNewswire · 16d ago How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% Zacks · 31d ago Mizuho Raises Price Target on Tango Therapeutics to $40 From $36, Keeps Outperform Rating MT Newswires · 36d ago Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues Insider Monkey · 38d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.